Introduction
Materials and methods
Human neuropathological assessment
Sample preparation
Quantification of AD-related proteins
Statistical analysis
Results
APOE genotype influences neuropathology in the elderly
Variable | APOE2 (N = 45) | APOE3 (N = 156) | APOE4 (N = 152) | P-value | |||
---|---|---|---|---|---|---|---|
N | Median (minimum, maximum) or No. (%) of patients | N | Median (minimum, maximum) or No. (%) of patients | N | Median (minimum, maximum) or No. (%) of patients | ||
Age at death (years) | 45 | 89 (69, 101) | 156 | 89 (59, 100) | 152 | 84 (54, 103) | < 0.001 |
Sex (Male) | 45 | 19 (42.2%) | 156 | 71 (45.5%) | 152 | 84 (55.3%) | 0.14 |
MMSE score | 19 | 25 (17, 29) | 83 | 27 (18, 30) | 31 | 27 (18, 29) | 0.083 |
Braak stage | 45 | 154 | 148 | < 0.001 | |||
0 | 0 (0.0%) | 4 (2.6%) | 2 (1.4%) | ||||
1 | 5 (11.1%) | 17 (11.0%) | 6 (4.1%) | ||||
2 | 13 (28.9%) | 40 (26.0%) | 8 (5.4%) | ||||
3 | 11 (24.4%) | 32 (20.8%) | 12 (8.1%) | ||||
4 | 6 (13.3%) | 34 (22.1%) | 24 (16.2%) | ||||
5 | 4 (8.9%) | 21 (13.6%) | 38 (25.7%) | ||||
6 | 6 (13.3%) | 6 (3.9%) | 58 (39.2%) | ||||
Thal phase | 28 | 105 | 59 | < 0.001 | |||
0 | 9 (32.1%) | 22 (21.0%) | 5 (8.5%) | ||||
1 | 5 (17.9%) | 26 (24.8%) | 3 (5.1%) | ||||
2 | 2 (7.1%) | 12 (11.4%) | 5 (8.5%) | ||||
3 | 6 (21.4%) | 30 (28.6%) | 10 (16.9%) | ||||
4 | 2 (7.1%) | 5 (4.8%) | 6 (10.2%) | ||||
5 | 4 (14.3%) | 10 (9.5%) | 30 (50.8%) | ||||
VaD | 45 | 20 (44.4%) | 156 | 62 (39.7%) | 152 | 41 (27.0%) | 0.019 |
CAA | 45 | 5 (11.1%) | 156 | 6 (3.8%) | 152 | 13 (8.6%) | 0.088 |
TDP-43 | 45 | 2 (4.4%) | 156 | 6 (3.8%) | 152 | 19 (12.5%) | 0.012 |
Synuclein | 45 | 9 (20.0%) | 156 | 25 (16.0%) | 152 | 50 (32.9%) | 0.002 |
Variable | APOE2 present | APOE2 absent | Unadjusted analysis | Adjusting for age and sex | ||||
---|---|---|---|---|---|---|---|---|
N | Median (minimum, maximum) or No. (%) of subjects | N | Median (minimum, maximum) or No. (%) of subjects | Estimate (95% CI) | P-value | Estimate (95% CI) | P-value | |
Neuritic plaque score | 45 | 308 | 0.44 (0.25, 0.78) | 0.005 | 0.49 (0.28, 0.87) | 0.015 | ||
0 | 20 (44.4%) | 60 (19.5%) | ||||||
1 | 4 (8.9%) | 62 (20.1%) | ||||||
2 | 10 (22.2%) | 76 (24.7%) | ||||||
3 | 11 (24.4%) | 110 (35.7%) | ||||||
AD-tau | 45 | 16 (35.6%) | 302 | 181 (59.9%) | 0.37 (0.19, 0.70) | 0.003 | 0.40 (0.20, 0.78) | 0.007 |
AGD-tau | 45 | 11 (24.4%) | 308 | 40 (13.0%) | 2.17 (0.98, 4.51) | 0.045 | 1.89 (0.84, 4.00) | 0.11 |
Variable | APOE4 present | APOE4 absent | Unadjusted analysis | Adjusting for age and sex | ||||
---|---|---|---|---|---|---|---|---|
N | Median (minimum, maximum) or No. (%) of subjects | N | Median (minimum, maximum) or No. (%) of subjects | Estimate (95% CI) | P-value | Estimate (95% CI) | P-value | |
Neuritic plaque score | 152 | 201 | 5.31 (3.51, 8.05) | < 0.001 | 4.86 (3.17, 7.46) | < 0.001 | ||
0 | 7 (4.6%) | 73 (36.3%) | ||||||
1 | 26 (17.1%) | 40 (19.9%) | ||||||
2 | 37 (24.3%) | 49 (24.4%) | ||||||
3 | 82 (53.9%) | 39 (19.4%) | ||||||
AD-tau | 148 | 120 (81.1%) | 199 | 77 (38.7%) | 6.79 (4.16, 11.36) | < 0.001 | 6.34 (3.83, 10.76) | < 0.001 |
AGD-tau | 152 | 13 (8.6%) | 201 | 38 (18.9%) | 0.40 (0.20, 0.76) | 0.007 | 0.49 (0.24, 0.95) | 0.041 |
AD-tau pathology is associated with cognitive impairment
APOE genotype influences the levels of AD-related molecules in the temporal cortex
N | β (95% CI) | P-value | |
---|---|---|---|
APOE2 vs. APOE3 (reference) | APOE2 (N = 45) vs. APOE3 (N = 156) | ||
Aβ40-TBS | 174 | 0.36 (− 0.36, 1.08) | 0.32 |
Aβ40-TBSX | 188 | − 0.26 (− 0.78, 0.26) | 0.33 |
Aβ40-FA | 188 | 1.12 (− 2.61, 4.86) | 0.55 |
Aβ42-TBS | 186 | 0.31 (− 0.84, 1.46) | 0.59 |
Aβ42-TBSX | 192 | − 0.98 (− 2.02, 0.06) | 0.064 |
Aβ42-FA | 197 | − 1.07 (− 12.12, 9.99) | 0.85 |
apoE-TBS | 196 | 0.61 (0.29, 0.93) | < 0.001 |
apoE-TBSX | 194 | − 0.11 (− 0.26, 0.04) | 0.14 |
apoE-FA | 197 | 0.03 (− 0.46, 0.52) | 0.91 |
tTau-TBS | 176 | − 2.44 (− 7.41, 2.53) | 0.33 |
tTau-TBSX | 194 | − 0.03 (− 0.19, 0.12) | 0.66 |
tTau-FA | 201 | 0.14 (− 0.02, 0.29) | 0.079 |
pTau181-TBS | 194 | − 0.05 (− 0.23, 0.13) | 0.56 |
pTau181-TBSX | 194 | − 0.08 (− 0.21, 0.04) | 0.18 |
pTau181-FA | 192 | − 0.01 (− 0.27, 0.25) | 0.94 |
APOE4 vs. APOE3 (reference) | APOE4 (N = 152) vs. APOE3 (N = 156) | ||
Aβ40-TBS | 267 | 0.82 (0.25, 1.39) | 0.005 |
Aβ40-TBSX | 292 | 0.99 (0.51, 1.48) | < 0.001 |
Aβ40-FA | 290 | 14.04 (9.94, 18.15) | < 0.001 |
Aβ42-TBS | 289 | 2.29 (1.63, 2.96) | < 0.001 |
Aβ42-TBSX | 293 | 2.51 (1.88, 3.14) | < 0.001 |
Aβ42-FA | 303 | 24.96 (18.17, 31.75) | < 0.001 |
apoE-TBS | 303 | − 0.29 (− 0.51, − 0.06) | 0.012 |
apoE-TBSX | 296 | 0.13 (0.02, 0.23) | 0.016 |
apoE-FA | 302 | 1.24 (0.85, 1.64) | < 0.001 |
tTau-TBS | 278 | − 1.62 (− 5.16, 1.91) | 0.37 |
tTau-TBSX | 296 | − 0.18 (− 0.30, − 0.07) | 0.002 |
tTau-FA | 308 | − 0.13 (− 0.24, − 0.03) | 0.013 |
pTau181-TBS | 297 | − 0.14 (− 0.26, − 0.03) | 0.017 |
pTau181-TBSX | 295 | − 0.06 (− 0.15, 0.02) | 0.14 |
pTau181-FA | 296 | 0.72 (0.49, 0.95) | < 0.001 |
Neuropathological measures are associated with the levels of AD-related molecules in the temporal cortex
Variable | N | Unadjusted analysis | Adjusting for age and sex | Full multivariable analysis | |||
---|---|---|---|---|---|---|---|
β (95% CI) | P-value | β (95% CI) | P-value | β (95% CI) | P-value | ||
Association with Aβ40-FA | |||||||
Age | 333 | − 2.58 (− 5.02, − 0.14) | 0.038 | − 2.45 (− 4.95, 0.06) | 0.056 | 0.60 (− 1.64, 2.83) | 0.60 |
Sex | 333 | 1.79 (− 2.06, 5.64) | 0.36 | 0.91 (− 3.03, 4.85) | 0.65 | − 0.62 (− 4.07, 2.83) | 0.72 |
APOE4 | 333 | 14.02 (10.43, 17.60) | < 0.001 | 13.87 (10.15, 17.59) | < 0.001 | 8.78 (4.93, 12.62) | < 0.001 |
VaD | 333 | − 1.43 (− 5.46, 2.60) | 0.49 | − 0.98 (− 5.06, 3.11) | 0.64 | − 0.41 (− 3.98, 3.16) | 0.82 |
CAA | 333 | 22.92 (15.89, 29.96) | < 0.001 | 22.76 (15.67, 29.84) | < 0.001 | 20.94 (14.49, 27.40) | < 0.001 |
Neuritic plaque score | 333 | 6.05 (4.53, 7.57) | < 0.001 | 5.97 (4.43, 7.52) | < 0.001 | 2.67 (0.62, 4.71) | 0.011 |
TDP-43 | 333 | 0.44 (− 6.88, 7.76) | 0.91 | 0.82 (− 6.51, 8.15) | 0.83 | − 3.81 (− 10.17, 2.55) | 0.24 |
Synuclein | 333 | 5.54 (1.08, 9.99) | 0.015 | 4.80 (0.27, 9.33) | 0.038 | 0.17 (− 3.85, 4.19) | 0.93 |
AD-tau | 327 | 12.48 (8.77, 16.19) | < 0.001 | 12.23 (8.46, 16.01) | < 0.001 | 4.39 (− 0.28, 9.06) | 0.065 |
AGD-tau | 333 | − 7.71 (− 13.13, − 2.28) | 0.006 | − 7.02 (− 12.52, − 1.52) | 0.012 | − 2.40 (− 7.28, 2.49) | 0.33 |
Association with Aβ42-FA | |||||||
Age | 348 | − 4.10 (− 8.31, 0.12) | 0.057 | − 4.15 (− 8.50, 0.20) | 0.062 | 2.71 (− 0.70, 6.11) | 0.12 |
Sex | 348 | 1.25 (− 5.53, 8.03) | 0.72 | − 0.34 (− 7.30, 6.61) | 0.92 | 1.47 (− 3.80, 6.73) | 0.58 |
APOE4 | 348 | 25.05 (18.75, 31.36) | < 0.001 | 25.30 (18.69, 31.90) | < 0.001 | 7.60 (1.68, 13.53) | 0.012 |
VaD | 348 | − 0.66 (− 7.78, 6.45) | 0.86 | 0.46 (− 6.77, 7.68) | 0.90 | 3.48 (− 1.99, 8.95) | 0.21 |
CAA | 348 | 20.19 (6.72, 33.66) | 0.003 | 19.91 (6.34, 33.47) | 0.004 | 14.11 (3.86, 24.35) | 0.007 |
Neuritic plaque score | 348 | 18.06 (15.85, 20.27) | < 0.001 | 18.31 (16.05, 20.57) | < 0.001 | 13.03 (9.93, 16.13) | < 0.001 |
TDP-43 | 348 | 11.83 (− 0.77, 24.44) | 0.066 | 12.04 (− 0.60, 24.67) | 0.062 | 0.18 (− 9.42, 9.77) | 0.97 |
Synuclein | 348 | 11.02 (3.15, 18.88) | 0.006 | 9.97 (1.94, 18.00) | 0.015 | − 1.23 (− 7.39, 4.94) | 0.70 |
AD-tau | 342 | 35.46 (29.68, 41.25) | < 0.001 | 35.42 (29.50, 41.34) | < 0.001 | 12.27 (5.23, 19.31) | < 0.001 |
AGD-tau | 348 | − 19.91 (− 29.26, − 10.56) | < 0.001 | − 19.18 (− 28.66, − 9.70) | < 0.001 | − 3.81 (− 11.20, 3.58) | 0.31 |
Association with apoE-FA | |||||||
Age | 346 | − 0.53 (− 0.76, − 0.29) | < 0.001 | − 0.51 (− 0.75, − 0.27) | < 0.001 | − 0.25 (− 0.48, − 0.02) | 0.031 |
Sex | 346 | 0.30 (− 0.08, 0.69) | 0.12 | 0.12 (− 0.26, 0.51) | 0.53 | 0.14 (− 0.20, 0.49) | 0.42 |
APOE4 | 346 | 1.39 (1.03, 1.76) | < 0.001 | 1.25 (0.88, 1.63) | < 0.001 | 0.79 (0.39, 1.18) | < 0.001 |
VaD | 346 | − 0.36 (− 0.76, 0.05) | 0.082 | − 0.24 (− 0.64, 0.17) | 0.25 | − 0.09 (− 0.45, 0.28) | 0.63 |
CAA | 346 | 1.26 (0.51, 2.02) | 0.001 | 1.17 (0.43, 1.91) | 0.002 | 0.82 (0.15, 1.49) | 0.016 |
Neuritic plaque score | 346 | 0.74 (0.59, 0.89) | < 0.001 | 0.70 (0.55, 0.85) | < 0.001 | 0.65 (0.44, 0.85) | < 0.001 |
TDP-43 | 346 | 0.43 (− 0.30, 1.17) | 0.25 | 0.51 (− 0.21, 1.23) | 0.16 | 0.04 (− 0.61, 0.69) | 0.91 |
Synuclein | 346 | 0.55 (0.09, 1.00) | 0.018 | 0.38 (− 0.07, 0.83) | 0.10 | − 0.15 (− 0.56, 0.26) | 0.47 |
AD-tau | 340 | 1.08 (0.70, 1.46) | < 0.001 | 0.96 (0.58, 1.34) | < 0.001 | − 0.30 (− 0.77, 0.16) | 0.20 |
AGD-tau | 346 | − 0.64 (− 1.19, − 0.10) | 0.021 | − 0.48 (− 1.03, 0.06) | 0.080 | 0.04 (− 0.45, 0.54) | 0.86 |
Association with tTau-FA | |||||||
Age | 353 | 0.03 (− 0.03, 0.09) | 0.29 | 0.03 (− 0.03, 0.09) | 0.37 | 0.00 (-0.07, 0.06) | 0.92 |
Sex | 353 | − 0.04 (− 0.14, 0.06) | 0.41 | − 0.03 (− 0.13, 0.07) | 0.56 | − 0.03 (− 0.13, 0.07) | 0.52 |
APOE4 | 353 | − 0.16 (− 0.26, − 0.06) | 0.001 | − 0.16 (− 0.26, − 0.05) | 0.003 | − 0.11 (− 0.22, 0.00) | 0.059 |
VaD | 353 | 0.01 (− 0.09, 0.12) | 0.79 | 0.01 (− 0.10, 0.11) | 0.88 | 0.02 (− 0.09, 0.12) | 0.74 |
CAA | 353 | − 0.06 (− 0.26, 0.13) | 0.52 | − 0.05 (− 0.25, 0.14) | 0.60 | − 0.05 (− 0.25, 0.14) | 0.61 |
Neuritic plaque score | 353 | − 0.04 (− 0.09, − 0.00) | 0.041 | − 0.04 (− 0.09, 0.00) | 0.055 | 0.01 (− 0.05, 0.06) | 0.82 |
TDP-43 | 353 | − 0.13 (− 0.32, 0.05) | 0.15 | − 0.14 (− 0.33, 0.04) | 0.13 | − 0.08 (− 0.27, 0.10) | 0.37 |
Synuclein | 353 | − 0.11 (− 0.22, 0.01) | 0.069 | − 0.10 (− 0.21, 0.02) | 0.11 | − 0.08 (− 0.20, 0.04) | 0.21 |
AD-tau | 347 | − 0.15 (− 0.25, − 0.05) | 0.003 | − 0.15 (− 0.25, − 0.05) | 0.004 | − 0.11 (− 0.25, 0.02) | 0.098 |
AGD-tau | 353 | 0.08 (− 0.06, 0.22) | 0.27 | 0.07 (− 0.08, 0.21) | 0.36 | 0.02 (− 0.12, 0.17) | 0.74 |
Association with pTau181-FA | |||||||
Age | 340 | − 0.39 (− 0.52, − 0.25) | < 0.001 | − 0.40 (− 0.54, − 0.26) | < 0.001 | − 0.22 (− 0.34, − 0.10) | < 0.001 |
Sex | 340 | 0.06 (− 0.17, 0.29) | 0.62 | − 0.10 (− 0.32, 0.13) | 0.39 | − 0.07 (− 0.26, 0.12) | 0.45 |
APOE4 | 340 | 0.85 (0.64, 1.07) | < 0.001 | 0.74 (0.53, 0.96) | < 0.001 | 0.28 (0.07, 0.49) | 0.010 |
VaD | 340 | − 0.08 (− 0.32, 0.15) | 0.49 | 0.04 (− 0.19, 0.27) | 0.73 | 0.10 (− 0.10, 0.29) | 0.34 |
CAA | 340 | 0.46 (0.02, 0.90) | 0.041 | 0.44 (0.01, 0.87) | 0.044 | 0.29 (− 0.06, 0.65) | 0.10 |
Neuritic plaque score | 340 | 0.52 (0.44, 0.61) | < 0.001 | 0.49 (0.41, 0.57) | < 0.001 | 0.31 (0.20, 0.42) | < 0.001 |
TDP-43 | 340 | 0.39 (− 0.04, 0.83) | 0.077 | 0.41 (− 0.01, 0.83) | 0.056 | 0.03 (− 0.32, 0.38) | 0.87 |
Synuclein | 340 | 0.35 (0.09, 0.62) | 0.009 | 0.22 (− 0.04, 0.49) | 0.092 | − 0.08 (− 0.30, 0.14) | 0.50 |
AD-tau | 334 | 1.09 (0.89, 1.28) | < 0.001 | 1.00 (0.81, 1.20) | < 0.001 | 0.41 (0.16, 0.66) | 0.002 |
AGD-tau | 340 | − 0.57 (− 0.90, − 0.24) | < 0.001 | − 0.48 (− 0.80, − 0.17) | 0.003 | − 0.08 (− 0.35, 0.19) | 0.57 |
APOE4 is associated with AD-related molecules in the absence of AGD-tau
N | No tau pathology: AD-tau ( −), AGD-tau ( −) | AD-tau pathology only AD-tau ( +), AGD-tau ( −) | Mixed tauopathy AD-tau (+ / −), AGD-tau ( +) | APOE x tau pathology interaction | ||||
---|---|---|---|---|---|---|---|---|
β (95% CI) | P-value | β (95% CI) | P-value | β (95% CI) | P-value | Interaction p-value | ||
APOE2 vs. APOE3 (reference) | APOE2 (N = 21) vs APOE3 (N = 73) | APOE2 (N = 13) vs APOE3 (N = 54) | APOE2 (N = 11) vs APOE3 (N = 27) | |||||
Aβ40-TBS | 174 | 0.90 (− 0.20 to 1.99) | 0.11 | 0.12 (− 1.26 to 1.49) | 0.86 | − 0.72 (− 2.08–0.63) | 0.28 | 0.45 |
Aβ40-TBSX | 188 | 0.27 (− 0.51 to 1.05) | 0.49 | − 0.32 (− 1.41 to 0.77) | 0.56 | − 0.94 (− 1.80, 0.08) | 0.034 | 0.14 |
Aβ40-FA | 188 | 1.47 (− 3.72 to 6.67) | 0.57 | 1.16 (− 7.28 to 9.61) | 0.78 | 3.05 (− 2.25 to 8.34) | 0.25 | 0.95 |
Aβ42-TBS | 186 | 0.09 (− 1.38 to 1.56) | 0.90 | 1.52 (− 0.73 to 3.76) | 0.18 | 0.42 (− 1.86 to 2.70) | 0.71 | 0.60 |
Aβ42-TBSX | 192 | − 0.19 (− 1.45 to 1.07) | 0.77 | 0.00 (− 1.84 to 1.84) | 1.00 | − 2.47 (− 4.64, 0.30) | 0.027 | 0.11 |
Aβ42-FA | 197 | 1.86 (− 12.81 to 16.52) | 0.80 | 6.19 (− 11.78 to 24.17) | 0.49 | − 3.16 (− 25.26 to 18.93) | 0.77 | 0.77 |
apoE-TBS | 196 | 0.52 (0.02 to 1.03) | 0.042 | 0.56 (− 0.02 to 1.15) | 0.059 | 0.75 (0.18to 1.32) | 0.012 | 0.90 |
apoE-TBSX | 194 | − 0.04 (− 0.27 to 0.18) | 0.70 | − 0.17 (− 0.43 to 0.08) | 0.18 | − 0.19 (− 0.52 to 0.14) | 0.26 | 0.64 |
apoE-FA | 197 | 0.17 (− 0.59 to 0.93) | 0.66 | 0.06 (− 0.88 to 1.00) | 0.90 | 0.07 (− 0.81 to 0.95) | 0.87 | 0.89 |
tTau-TBS | 176 | − 7.27 (-14.55, 0.00) | 0.050 | 3.50 (-6.45 to 13.44) | 0.48 | − 1.75 (− 12.13 to 8.64) | 0.73 | 0.18 |
tTau-TBSX | 194 | − 0.05 (− 0.25 to 0.16) | 0.67 | 0.08 (− 0.24 to 0.39) | 0.63 | − 0.19 (− 0.46 to 0.09) | 0.18 | 0.51 |
tTau-FA | 201 | − 0.05 (− 0.30 to 0.20) | 0.69 | 0.35 (0.10 to 0.60) | 0.007 | 0.25 (− 0.06 to 0.55) | 0.11 | 0.061 |
pTau181-TBS | 194 | − 0.01 (− 0.25 to 0.22) | 0.92 | − 0.08 (− 0.41 to 0.24) | 0.61 | − 0.34 (− 0.72 to 0.04) | 0.075 | 0.23 |
pTau181-TBSX | 194 | − 0.19 (− 0.38 to 0.01) | 0.058 | 0.10 (− 0.10 to 0.31) | 0.32 | − 0.20 (− 0.46 to 0.06) | 0.13 | 0.10 |
pTau181-FA | 192 | − 0.24 (− 0.44, 0.03) | 0.023 | 0.46 (− 0.18 to 1.10) | 0.15 | 0.24 (− 0.14 to 0.62) | 0.21 | 0.065 |
APOE4 vs. APOE3 (reference) | APOE4 (N = 20) vs APOE3 (N = 73) | APOE4 (N = 115) vs APOE3 (N = 54) | APOE4 (N = 13) vs APOE3 (N = 27) | |||||
Aβ40-TBS | 267 | 0.48 (− 0.52 to 1.49) | 0.34 | 0.85 (− 0.07 to 1.77) | 0.069 | − 0.63 (− 1.98 to 0.71) | 0.34 | 0.50 |
Aβ40-TBSX | 292 | 0.12 (− 0.68 to 0.93) | 0.76 | 1.31 (0.51 to 2.11) | 0.002 | − 0.14 (− 0.74 to 0.47) | 0.65 | 0.049 |
Aβ40-FA | 290 | 7.21 (− 0.05 to 14.48) | 0.052 | 14.15 (7.47 to 20.83) | < 0.001 | 1.44 (− 3.49 to 6.37) | 0.56 | 0.088 |
Aβ42-TBS | 289 | 2.68 (1.34 to 4.02) | < 0.001 | 1.08 (0.19 to 1.96) | 0.017 | 2.09 (− 0.13 to 4.32) | 0.064 | 0.11 |
Aβ42-TBSX | 293 | 2.18 (0.80 to 3.57) | 0.002 | 1.07 (0.36 to 1.79) | 0.004 | 2.98 (0.99 to 4.97) | 0.004 | 0.10 |
Aβ42-FA | 303 | 21.79 (6.52 to 37.07) | 0.006 | 9.15 (1.22 to 17.07) | 0.024 | 26.52 (7.49 to 45.55) | 0.008 | 0.16 |
apoE-TBS | 303 | − 0.29 (− 0.80 to 0.22) | 0.26 | − 0.33 (− 0.65, 0.02) | 0.036 | 0.27 (− 0.25 to 0.79) | 0.30 | 0.32 |
apoE-TBSX | 296 | − 0.03 (− 0.28 to 0.22) | 0.82 | 0.22 (0.08 to 0.36) | 0.002 | 0.02 (− 0.27 to 0.31) | 0.89 | 0.087 |
apoE-FA | 302 | 0.31 (− 0.46 to 1.08) | 0.43 | 1.41 (0.82 to 2.01) | < 0.001 | 0.91 (− 0.15 to 1.96) | 0.091 | 0.085 |
tTau-TBS | 278 | − 0.34 (− 7.37 to 6.69) | 0.92 | 1.01 (− 4.32 to 6.34) | 0.71 | − 1.23 (− 10.56 to 8.09) | 0.79 | 0.85 |
tTau-TBSX | 296 | 0.01 (− 0.21 to 0.23) | 0.91 | − 0.09 (− 0.26 to 0.07) | 0.25 | 0.05 (− 0.23 to 0.33) | 0.71 | 0.76 |
tTau-FA | 308 | 0.02 (− 0.23 to 0.27) | 0.89 | − 0.09 (− 0.23 to 0.05) | 0.19 | − 0.08 (− 0.38 to 0.22) | 0.60 | 0.76 |
pTau181-TBS | 297 | − 0.11 (− 0.36 to 0.13) | 0.37 | − 0.03 (− 0.20 to 0.15) | 0.77 | − 0.18 (− 0.42 to 0.07) | 0.16 | 0.79 |
pTau181-TBSX | 295 | − 0.23 (− 0.44, 0.03) | 0.024 | 0.09 (− 0.02 to 0.21) | 0.10 | − 0.22 (− 0.44 to 0.00) | 0.052 | 0.004 |
pTau181-FA | 296 | 0.18 (− 0.04–0.40) | 0.12 | 0.60 (0.24 to 0.97) | 0.001 | 0.04 (− 0.33 to 0.40) | 0.85 | 0.067 |